Advertisement

Hepatitis Arthritis: HBV and HCV

  • Rodolfo Perez-Alamino
Chapter

Abstract

Viral infections are a well-recognized cause of arthralgia and arthritis. Diagnosis of virally induced arthritis can be difficult to confirm but should be considered in all patients presenting with acute-onset polyarticular symptoms. Hepatitis B and C infections are frequently recognized as causative agents of arthritis. This manifestation could be the only presenting feature of acute HBV and HCV infection and often resembles rheumatoid arthritis, with a symmetrical polyarticular distribution. HCV chronic infection is usually associated with arthralgia, myalgia, cryoglobulinemia vasculitis, sicca syndrome, and a vast array of autoantibodies production. Previous treatment of HCV has been based on interferon, which has been associated with poor efficacy, high rates of side effects, and risk of exacerbation of autoimmune diseases. Actually, the new oral interferon-free regimens offer the opportunity for those patients to be cured with a low risk of side effects and a short treatment duration.

Keywords

Hepatitis B Hepatitis C Rheumatic manifestations Arthritis Arthralgia Myalgia Cryoglobulinemia Vasculitis Sicca syndrome Interferon Direct antiviral agents Immunosuppressants Rituximab 

References

  1. 1.
    Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107.CrossRefGoogle Scholar
  2. 2.
    Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053–63.CrossRefGoogle Scholar
  3. 3.
    Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486–500.CrossRefGoogle Scholar
  4. 4.
    Iqbal K, Klevens RM, Kainer MA, et al. Epidemiology of acute hepatitis B in the United States from population-based surveillance, 2006-2011. Clin Infect Dis. 2015;61:584–92.CrossRefGoogle Scholar
  5. 5.
    Ferri C, Sebastiani M, Giuggioli D, et al. Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer. World J Hepatol. 2015;7:327–43.CrossRefGoogle Scholar
  6. 6.
    Cacoub P, Gragnani L, Comarmond C, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46(Suppl 5):S165–73.CrossRefGoogle Scholar
  7. 7.
    Zignego AL, Ferri C, Pileri SA, et al. Extrahepatic manifestations of hepatitis C virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis. 2007;39(1):2–17.CrossRefGoogle Scholar
  8. 8.
    Koutsianas C, Thomas K, Vassilopoulos D. Hepatitis B reactivation in rheumatic diseases. Screening and prevention. Rheum Dis Clin North Am. 2017;43(1):133–49.CrossRefGoogle Scholar
  9. 9.
    Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–83.CrossRefGoogle Scholar
  10. 10.
    Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations. World J Gastroenterol. 2015;21:10274–89.CrossRefGoogle Scholar
  11. 11.
    Phillips S, Chokshi S, Riva A, et al. CD8(1) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol. 2010;184:287–95.CrossRefGoogle Scholar
  12. 12.
    Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut. 2012;61:1754–64.CrossRefGoogle Scholar
  13. 13.
    Tzeng HT, Tsai HF, Chyuan IT, Liao HJ, Chen CJ, Chen PJ, Hsu PN. Tumor necrosis factor-alpha induced by hepatitis B virus core mediating the immune response for hepatitis B viral clearance in mice model. PLoS One. 2014;9:e103008.CrossRefGoogle Scholar
  14. 14.
    Zhang JY, Zhang Z, Lin F, et al. Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology. 2010;51:81–91.CrossRefGoogle Scholar
  15. 15.
    Marra F, Aleffi S, Galastri S, Provenzano A. Mononuclear cells in liver fibrosis. Semin Immunopathol. 2009;31:345–58.CrossRefGoogle Scholar
  16. 16.
    Inman RD. Rheumatic manifestations of hepatitis B virus infection. Semin Arthritis Rheum. 1982;11:406–20.CrossRefGoogle Scholar
  17. 17.
    Vassilopoulos D, Calabrese LH. Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations. Arthritis Res Ther. 2008;10:215.CrossRefGoogle Scholar
  18. 18.
    Cacoub P, Commarmond C, Sadoun D, Desbois AC. Hepatitis C virus infection and rheumatic diseases. The impact of direct-acting antiviral agent. Rheum Dis Clin North Am. 2017;43(1):123–32.CrossRefGoogle Scholar
  19. 19.
    Zuckerman E, Yeshurun D, Rosner I. Management of hepatitis C virus-related arthritis. BioDrugs. 2001;15(9):573–84.CrossRefGoogle Scholar
  20. 20.
    Olivieri I, Palazzi C, Padula A. Hepatitis C virus and arthritis. Rheum Dis Clin N Am. 2003;29:111–22.CrossRefGoogle Scholar
  21. 21.
    Cacoub P, Commarmond C. New insights into HCV-related rheumatologic disorders: a review. J Adv Res. 2017;8(2):89–97.CrossRefGoogle Scholar
  22. 22.
    Terrier B, Semoun O, Saadoun D, et al. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum. 2011;63:1748–57.CrossRefGoogle Scholar
  23. 23.
    Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoblobulinaemias. Lancet. 2012;379(9813):348–60.CrossRefGoogle Scholar
  24. 24.
    Terrier B, Joly F, Vazquez T, et al. Expansion of functionally anergic CD21 /low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity. J Immunol. 1950;2011(187):6550–63.Google Scholar
  25. 25.
    Caussin-Schwemling C, Schmitt C, Stoll-Keller F. Study of the infection of human blood derived monocyte/macrophages with hepatitis C virus in vitro. J Med Virol. 2001;65:14–22.CrossRefGoogle Scholar
  26. 26.
    Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999;42:2204–12.CrossRefGoogle Scholar
  27. 27.
    Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d’Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l’Hepatite C. Medicine (Baltimore). 2000;79:47–56.CrossRefGoogle Scholar
  28. 28.
    Younossi Z, Park H, Henry L, et al. Extra-hepatic manifestations of hepatitis C—a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016;150(7):1599–608.CrossRefGoogle Scholar
  29. 29.
    Brito-Zerón P, Gheitasi H, Retamozo S, et al. How hepatitis C virus modifies the immunological profile of Sjogren syndrome: analysis of 783 patients. Arthritis Res Ther. 2015;17:250.CrossRefGoogle Scholar
  30. 30.
    Arrieta JJ, Rodríguez-Iñigo E, Ortiz-Movilla N, et al. In situ detection of hepatitis C virus RNA in salivary glands. Am J Pathol. 2001;158:259–64.CrossRefGoogle Scholar
  31. 31.
    American Association for the Study of Liver Diseases. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.CrossRefGoogle Scholar
  32. 32.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.CrossRefGoogle Scholar
  33. 33.
    Lee HW, Lee HJ, Hwang JS, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology. 2010;51:415–21.CrossRefGoogle Scholar
  34. 34.
    Mazzaro C, Zorat F, Caizzi M, et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol. 2005;42:632–8.CrossRefGoogle Scholar
  35. 35.
    Saadoun D, Resche-Rigon M, Thibault V, et al. Antiviral therapy for hepatitis C virus– associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum. 2006;54:3696–706.CrossRefGoogle Scholar
  36. 36.
    Onishi S, Nagashima T, Kimura H, et al. Systemic lupus erythematosus and Sjogren’s syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C. Lupus. 2010;19:753–5.CrossRefGoogle Scholar
  37. 37.
    Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98.CrossRefGoogle Scholar
  38. 38.
    Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–21.CrossRefGoogle Scholar
  39. 39.
    Pol S, Corouge M, Vallet-Pichard A. Daclatasvir-sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life. Hepat Med. 2016;8:21–6.CrossRefGoogle Scholar
  40. 40.
    Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016;75(10):1777–82.CrossRefGoogle Scholar
  41. 41.
    Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63:408–17.CrossRefGoogle Scholar
  42. 42.
    De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843–53.CrossRefGoogle Scholar
  43. 43.
    Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:835–42.CrossRefGoogle Scholar
  44. 44.
    Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116:326–34.CrossRefGoogle Scholar
  45. 45.
    Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood. 2010;116:343–53.CrossRefGoogle Scholar
  46. 46.
    Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood. 1994;84:3336–43.PubMedGoogle Scholar
  47. 47.
    Hausfater P, Cacoub P, Assogba U, et al. Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis. Nephron. 2002;91:627–30.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Rodolfo Perez-Alamino
    • 1
  1. 1.Rheumatology Section, Department of Internal MedicineHospital AvellanedaTucumánArgentina

Personalised recommendations